Novel ATR/PARP1 Dual Inhibitors Demonstrate Synergistic Antitumor Efficacy in Triple‐Negative Breast Cancer Models
Advanced Science · 2025-08 · 12 (29)
DOI: 10.1002/advs.202501916 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 16.06.2025. Verfasst von Yuan Gao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Institute, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang Provi…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Ataxia Telangiectasia Mutated Proteins, Poly (ADP-Ribose) Polymerase-1, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Department of Science and Technology, Medical Health Science and Technology Project of Zhejiang Provincial Health Commission, Ministry of Science and Technology of China (High-end foreign experts' program.
Abstract (Originalsprache)
Concomitant inhibition of ataxia telangiectasia and Rad3‐related protein (ATR) and poly ADP‐ribose Polymerase (PARP) pathways is a promising strategy in cancer therapy, potentially expanding the clinical utility of ATR inhibitor (ATRi) and PARP inhibitor (PARPi). A novel series of ATR/PARP1 dual inhibitors is developed through the pharmacophore fusion of AZD6738 and Olaparib. Among them, B8 emerges as the most promising candidate, exhibiting potent ATR (IC 50 : 17.3 nM) and PARP1 (IC 50 : 0.38 nM) inhibition. B8 effectively reduced cell viability, induced apoptosis, and caused G2/M cell cycle arrest in TNBC cells. Additionally, B8 significantly impaired TNBC colony formation, migration, and invasion. Mechanistically, B8 induces DNA damage, evidenced by increased γ H2AX levels. In in vivo studies, B8 suppressed tumor growth more effectively than the combination in MDA‐MB‐468 xenografted mice, with no significant body weight loss. B8 also enhanced γ H2AX expression in tumor tissues. These findings confirm the synergistic effects of ATR/PARP1 co‐inhibition and highlight the potential of this novel inhibitor class for TNBC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Institute, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang Province, 310000, China.
- School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang Province, 310000, China.
- Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of…
- College of Life and Environmental Sciences, Hangzhou Normal University, Hangzhou, Zhejiang Province, 310000, China.
- Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People' s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang Province, 310000, China.
- School of Basic Medical Science, Hangzhou Normal University, Hangzhou, Zhejiang Province, 310000, China.
ORCID-Profile: Xiang-Yang Ye
Förderung
- Zhejiang Provincial Department of Science and Technology
- Medical Health Science and Technology Project of Zhejiang Provincial Health Commission
- Ministry of Science and Technology of China (High-end foreign experts' program
- Hangzhou's "115" plan to introduce overseas intelligence projects
- Zhejiang Provincial People's Hospital scientific research start-up funds
Zitieren
APA
Gao, Y., Zhou, J., Wang, C. C., Wang, Z. H., Mao, N. D., He, M. L., Zhang, P. P., Huang, P., Ye, G. W., Zhang, Y. Q., Tang, F. H., Zhang, H., Xie, T., & Ye, X. Y. (2025). Novel ATR/PARP1 Dual Inhibitors Demonstrate Synergistic Antitumor Efficacy in Triple‐Negative Breast Cancer Models. Advanced Science, 12(29). https://doi.org/10.1002/advs.202501916
Vancouver
Gao Y, Zhou J, Wang CC, Wang ZH, Mao ND, He ML, et al. Novel ATR/PARP1 Dual Inhibitors Demonstrate Synergistic Antitumor Efficacy in Triple‐Negative Breast Cancer Models. Advanced Science. 2025;12(29). doi:10.1002/advs.202501916
BibTeX
@article{Gao2025,
author = {Gao, Yuan and Zhou, Jiawei and Wang, Chen-Chen and Wang, Zong-Hao and Mao, Nian-Dong and He, Meng-Lan and Zhang, Peng-Peng and Huang, Ping and Ye, Guo-Wei and Zhang, Yu-Qing and Tang, Feng-Hui and Zhang, Hang and Xie, Tian and Ye, Xiang-Yang},
title = {Novel ATR/PARP1 Dual Inhibitors Demonstrate Synergistic Antitumor Efficacy in Triple‐Negative Breast Cancer Models},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {29},
doi = {10.1002/advs.202501916}
}
EUVIMED